New Rx for Multiple Myeloma
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments.
Leukemia is a cancer of the blood cells that most commonly occurs in adults older than 55 and is also the most common cancer in children younger than 15. There are currently more than 300,000 people estimated to be living with or in remission from leukemia in the US.
In Early Tests, Blood, Bone Marrow Rx Sparked Hope
Early testing of a medication for blood cancers and bone marrow disorders yielded promising results. Now, researchers are looking to the future.
What Babies Eat May Affect Leukemia Risk
Childhood cancer is rare, but it is still a leading health threat to children and adolescents — surpassed only by accidents. However, babies who are breastfed may be at a lower risk for developing one type of blood cancer in childhood.
FDA Approves Farydak for Treatment of Multiple Myeloma
The U.S. Food and Drug Administration today approved Farydak (panobinostat) for the treatment of patients with multiple myeloma.
First Drug Approved to Treat Waldenström’s Macroglobulinemia
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system.
Great Leaps in Leukemia Treatment
Cancer research has led to longer lives and better quality of life for millions of people. This year, the transformation of leukemia treatment has been singled out as the “Advance of the Year.”
Amgen's Leukemia Rx is Effective & Expensive
Earlier this month, the US Food and Drug Administration (FDA) approved a new type of treatment for a severe form of leukemia. That treatment becomes available Thursday, and the manufacturer has revealed how much it will cost.
Quality of Life May Raise Quantity of Life With Lymphoma
Feeling good about life may make it last a little longer. Lymphoma patients with high quality of life may live longer than those with lower life satisfaction.
FDA Approves First Test for Group of Human Retroviruses
The U.S. Food and Drug Administration today approved MP Diagnostics HTLV Blot 2.4, the first FDA-licensed supplemental test for Human T-cell Lymphotropic Virus-I/II (HTLV-I/II).